AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

12-Oct-2009 - Switzerland

AC Immune SA announced that it has entered a collaboration with Bayer Schering Pharma on the diagnostic imaging of Alzheimer´s Disease. Bayer´s novel positron emission tomography (PET) tracer florbetaben will be applied for imaging beta-Amyloid plaques in the brain of patients undergoing the Phase I clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24. This is the first time this PET tracer will be tested in treated Alzheimer’s patients.

Prof. Andrea Pfeifer, CEO of AC Immune said, “This collaboration with Bayer adds further value to our Alzheimer´s vaccine ACI-24. The adoption of a diagnostic imaging substance visualizing the deposition of beta-Amyloid that is targeted by our vaccine can be an important parameter for dose selection, and will provide useful complementary data. There is a key trend in the industry to co-develop therapy guiding diagnostics alongside drugs for patients. We look forward to working with Bayer´s experts in this ground-breaking collaboration.”

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Last viewed contents

Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593) - Balaglitazone is a novel TZD candidate for the treatment of diabetes mellitus

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

Evotec and Novo Nordisk form research alliance in diabetes and obesity

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema - Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor